A Combination Approach to the Toughest Lupus Kidney Cases

Lupus nephritis, kidney inflammation caused by systemic lupus erythematosus, is one of the more dangerous complications of lupus, and one of the hardest to fully resolve. Even with treatment, many patients don't reach a complete renal response, meaning their kidney function and protein levels don't fully normalize, which leaves them at ongoing risk of long-term kidney damage. Several individual drugs have been approved for lupus nephritis over the past few years, but each one, used alone, still leaves a meaningful share of patients short of complete remission.

Aurinia Pharmaceuticals announced on July 6, 2026, the launch of PRESERVE, a Phase 4 study built around a different idea: instead of testing another new single drug, it tests combinations. The trial pairs LUPKYNIS (voclosporin), Aurinia's already-approved oral therapy that protects kidney cells directly by stabilizing structures called podocytes and calming T-cell activation, with one of three newer biologics: belimumab, obinutuzumab, or anifrolumab. Each of those three works through a different mechanism, belimumab and obinutuzumab both target B cells, the antibody-producing immune cells central to lupus, while anifrolumab blocks type 1 interferon signaling, a separate inflammatory pathway implicated in the disease.

The logic behind combining rather than switching is straightforward: because LUPKYNIS, belimumab, obinutuzumab, and anifrolumab each work on a different part of the immune process driving kidney damage, hitting multiple pathways at once might stop nephron damage more quickly and preserve more long-term kidney function than any one drug alone. The study plans to enroll about 150 patients across roughly 50 sites in the United States, with the primary measure being the proportion of patients who reach complete renal response at 6 months, a meaningfully faster readout than older lupus nephritis trials have typically used.

This is a Phase 4 study, meaning it's being conducted after these drugs are already approved and on the market, specifically to answer a real-world clinical question rather than to win a new approval. That matters for patients: this isn't testing something years away from availability, it's testing how to use medications that are already accessible today, just combined differently than current practice typically does.

If you or someone you love has lupus nephritis that hasn't responded fully to a single therapy, this combination approach reflects where a lot of nephrology and rheumatology thinking is heading, and it's a reasonable study to ask your care team about, whether as a potential trial to join or simply as a preview of where combination treatment strategy may be headed in routine practice.